Luminex Corp (LMNX) Files 10-K for the Fiscal Year Ended on December 31, 2017
- By insider
Luminex Corp (LMNX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Luminex Corp develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Its products include MAGPIX, Luminex 100/200, & FLEXMAP 3D. Luminex Corp has a market cap of $889.470 million; its shares were traded at around $20.19 with a P/E ratio of 30.15 and P/S ratio of 2.85. The dividend yield of Luminex Corp stocks is 1.18%. Luminex Corp had annual average EBITDA growth of 17.50% over the past ten years. GuruFocus rated Luminex Corp the business predictability rank of 3-star.
Warning! GuruFocus has detected 2 Warning Signs with LMNX. Click here to check it out.
The intrinsic value of LMNX
For the last quarter Luminex Corp reported a revenue of $78.2 million, compared with the revenue of $72.27 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $306.6 million, an increase of 13.3% from last year. For the last five years Luminex Corp had an average revenue growth rate of 8.4% a year.
The reported diluted earnings per share was 67 cents for the year, an increase of 109.4% from previous year. Over the last five years Luminex Corp had an EPS growth rate of 18.2% a year. The Luminex Corp had a decent operating margin of 12.12%, compared with the operating margin of 7.75% a year before. The 10-year historical median operating margin of Luminex Corp is 9.58%. The profitability rank of the company is 8 (out of 10).
At the end of the fiscal year, Luminex Corp has the cash and cash equivalents of $127.1 million, compared with $93.5 million in the previous year. The company had no long term debt. The interest coverage to the debt is 7.9. Luminex Corp has a financial strength rank of 9 (out of 10).
At the current stock price of $20.19, Luminex Corp is traded at 34% discount to its historical median P/S valuation band of $30.58. The P/S ratio of the stock is 2.85, while the historical median P/S ratio is 4.32. The intrinsic value of the stock is $7.17 a share, according to GuruFocus DCF Calculator. The stock gained 10.28% during the past 12 months.
For the complete 20-year historical financial data of LMNX, click here.
This article first appeared on GuruFocus.
Warning! GuruFocus has detected 2 Warning Signs with LMNX. Click here to check it out.
The intrinsic value of LMNX
